POXEL news, videos and press releases - Page 3
For more news please use our advanced search feature.
POXEL - More news...
POXEL - More news...
- Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
- Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
- Poxel Announces Financial Calendar for 2022
- Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
- Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
- Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021
- Poxel Announces its Participation at Investor Conferences in October 2021
- Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)
- Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update
- Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients
- Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021
- Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
- Poxel Announces Its Participation at Investor and Scientific Conferences in September
- Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021
- Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements
- Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021
- Poxel Announces Results from June 23, 2021 Ordinary Annual and Extraordinary General Meeting
- Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
- Poxel Announces Participation and Presentations at the EASL (European Association for the Study of the Liver) International Liver CongressTM 2021
- Poxel Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)
- Poxel Announces Participation at Upcoming Virtual Investor Conferences in June
- Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021
- Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society
- Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit
- Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021
- Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update
- Poxel Announces Completion of Arbitration with Merck Serono
- Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
